ALK-Abelló

Regulatory Filings • Sep 6, 2011

ALK launches Jext® - a new adrenaline auto-injector for the emergency treatment
of severe acute allergic reactions - in most major European markets. Jext® has
a 33% longer shelf life than current standard treatment and is therefore more
cost-effective. The pen has been developed by ALK who owns the global product
rights.

Copenhagen, 2011-09-06 10:22 CEST (GLOBE NEWSWIRE) --

Today, ALK launches a new and improved adrenaline auto-injector - Jext®, which
has been developed for emergency treatment of severe acute allergic reactions
(anaphylaxis) in children and adults caused by, for example, foods or bee
stings.

Anaphylaxis is potentially life threatening and must be treated quickly and
effectively. Consequently, patients need to carry their adrenaline
auto-injector at all times. Jext® has a significantly increased shelf life of
24 months; 33% longer than current standard treatment. Additionally, it is the
only pen that can be kept at temperatures above 25°C and remain effective.
Finally, Jext® is the only adrenaline pen in Europe with a needle shield which
offers needle protection automatically after use. These improvements will
provide patients and their carers with confidence in carrying and using their
adrenaline pens.

“Jext® was designed to address the significant unmet needs of anaphylaxis
patients, carers, and healthcare professionals. ALK remains completely
dedicated to developing patient-friendly treatments that improve the quality of
life of people with allergy” says President and CEO Jens Bager.

Until recently, ALK has distributed an in-licensed adrenaline pen. With the
launch of Jext®, ALK expects to improve the company's gross margin and
substantially improve earnings from the business area within the next few
years.

This announcement does not change ALK's outlook for the financial year 2011.

ALK-Abelló A/S

Jens Bager
President and CEO

Contact: Jens Bager, President and CEO, tel. (+45) 4574 7576

Investor Relations: Per Plotnikof, tel. (+45) 4574 7527, mobile (+45) 2261 2525
Press: Martin Barlebo, tel. (+45) 4574 7901, mobile (+45) 2064 1143

About anaphylaxis
Anaphylaxis is a medical emergency and the first-line treatment is adrenaline.
Patients at risk of developing anaphylaxis are recommended to carry an
adrenaline auto-injector, which must be used immediately when symptoms of
anaphylaxis appear. It is estimated that in Europe and the USA there are up to
four million people carrying an adrenaline auto-injector. The current global
sales of adrenalin auto-injectors are estimated at more than EUR 165 million.

Since anaphylaxis has to be treated quickly and effectively, it is important
that adrenaline injectors are reliable, easy to use, and work correctly under
all circumstances. Find more information at www.life-saver.org.

About Jext®
Jext® is a new adrenaline auto-injector (AAI), indicated for use in the
emergency treatment of severe acute allergic reactions (anaphylaxis) to insect
stings or bites, foods, drugs and other allergens as well as idiopathic or
exercise induced anaphylaxis. Jext® can be used reliably, easily and correctly
in the emergency treatment of anaphylaxis. Jext® has a 33% longer shelf life
than the current standard of care. Jext® is available as of 6 September 2011 in
most major European markets.

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy - a unique treatment of the underlying cause of allergy. The
company has approximately 1,700 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii Pharmaceutical Co. Ltd. to commercialise
allergy immunotherapy tablets in North America and Japan, respectively. The
company is headquartered in Hørsholm, Denmark, and listed on the NASDAQ OMX
Copenhagen A/S. Find more information at www.alk-abello.com.